Related Experiment Video
Updated: Jul 2, 2026

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
Prevention of calcific aortic valve stenosis-fact or fiction?
Peter J Cawley1, Catherine M Otto
1Department of Medicine, University of Washington, Seattle, USA.
Insights
Calcific aortic valve stenosis is a complex disease. Current medical therapies like statins have not shown benefit in randomized trials, necessitating exploration of new treatments targeting early disease processes.
Area of Science:
- Cardiovascular Medicine
- Pathophysiology
- Pharmacology
Background:
- Calcific aortic valve stenosis (CAVS) is a progressive disease.
- Valve replacement is the only effective long-term treatment, but only for advanced cases.
- CAVS pathogenesis is now understood as an active inflammatory process, similar to atherosclerosis.
Purpose of the Study:
- To review the current understanding of CAVS pathogenesis.
- To evaluate the efficacy of medical therapies targeting CAVS.
- To discuss future therapeutic strategies for CAVS.
Main Methods:
- Review of current literature on CAVS pathogenesis.
- Analysis of clinical trial data for medical therapies (statins, renin-angiotensin inhibition).
- Discussion of potential future therapeutic targets and treatment timing.
Main Results:
- Statins have not demonstrated benefit in randomized controlled trials for CAVS.
- Renin-angiotensin inhibition has shown mixed results in retrospective studies, with no randomized data.
- Current medical therapies have not altered the disease course effectively.
Conclusions:
- Medical therapies targeting atherosclerosis pathways have not proven effective for CAVS.
- Future research should focus on novel therapies targeting specific pathways in early-stage CAVS.
- Optimal timing and duration for medical interventions in CAVS require further definition.
Abstract:
Valve replacement is the only long-term effective treatment for calcific aortic valve stenosis. However, this treatment is aimed only at patients with advanced leaflet disease and symptoms of left ventricular obstruction. Over the past 15 years, our understanding of the pathogenesis of calcific aortic stenosis has changed significantly: away from a passive degenerative disease to an active process involving endothelial dysfunction, lipid accumulation, an inflammatory infiltrate, and a regulated process of calcification. Since many of the same processes are characteristic of atherosclerosis, trials have been undertaken to test whether medical therapy (statins, renin-angiotensin inhibition) can prevent or alter the disease course. Although retrospective and non-randomized studies suggested a positive effect with statins, benefit has not been seen in perspective randomized controlled trials, although two major studies are still in progress. Inhibition of renin-angiotensin has shown discordant results in retrospective studies with no randomized controlled data published. In the future, we need to consider other medical therapies that might target different pathways in this disease process. In addition, we need to define the optimal timing and duration of therapy for this chronic slowly progressive disease; treatments aimed at the early disease process may be ineffective with end-stage tissue changes.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Atherosclerosis III: Management
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Coronary Artery Disease IV: Preventive Measures

